Anna Oaknin, MD
Hematologist-Oncologist
GEICO (Grupo Espanol de Investigacion en Cancer de Ovario)
Paseo de Vall Hebron, 119-129
Barcelona
Spain
08035
Papers:
4 - Seminal Abstract
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
143 - Scientific Plenary
Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study
144 - Scientific Plenary
High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: a Gynecologic Oncology Group (GOG) study